Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in acutely psychotic hospitalized Chinese adults with schizophrenia
NCT05919823Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Started May 2023; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05919823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919823.